Ypsomed Holding AG (YPHDF)
OTCMKTS
· Delayed Price · Currency is USD
417.98
+55.70 (15.37%)
At close: Apr 29, 2025
Ypsomed Holding AG Revenue
In the fiscal year ending March 31, 2025, Ypsomed Holding AG had annual revenue of 748.87M CHF with 36.54% growth. Ypsomed Holding AG had revenue of 324.01M in the half year ending September 30, 2024, with 32.66% growth.
Revenue
748.87M CHF
Revenue Growth
+36.54%
P/S Ratio
7.20
Revenue / Employee
326.16K CHF
Employees
2,296
Market Cap
6.10B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 748.87M | 200.41M | 36.54% |
Mar 31, 2024 | 548.46M | 51.00M | 10.25% |
Mar 31, 2023 | 497.46M | 32.62M | 7.02% |
Mar 31, 2022 | 464.84M | 61.19M | 15.16% |
Mar 31, 2021 | 403.66M | 9.39M | 2.38% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
BioStem Technologies | 332.45M |
Ypsomed Holding AG News
- 6 months ago - Novo Nordisk (NVO) Partners with Ypsomed for Next-Gen Obesity Drug Delivery - GuruFocus
- 6 months ago - Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens - Seeking Alpha